Headlee D - Search Results

1

Acute renal toxicity associated with suramin in the treatment of prostate cancer.

Figg WD, Cooper MR, Thibault A, Headlee D, Humphrey J, Bergan RC, Reed E, Sartor O. Figg WD, et al. Among authors: headlee d. Cancer. 1994 Sep 1;74(5):1612-4. doi: 10.1002/1097-0142(19940901)74:5<1612::aid-cncr2820740519>3.0.co;2-q. Cancer. 1994. PMID: 8062193

2

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.

Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, Steinberg S, Figg WD, Linehan WM, Myers CE. Sartor O, et al. Among authors: headlee d. J Natl Cancer Inst. 1994 Feb 2;86(3):222-7. doi: 10.1093/jnci/86.3.222. J Natl Cancer Inst. 1994. PMID: 7506794

3

A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer.

Figg WD, Thibault A, Cooper MR, Reid R, Headlee D, Dawson N, Kohler DR, Reed E, Sartor O. Figg WD, et al. Among authors: headlee d. Cancer. 1995 Apr 15;75(8):2159-64. doi: 10.1002/1097-0142(19950415)75:8<2159::aid-cncr2820750820>3.0.co;2-o. Cancer. 1995. PMID: 7535186 Clinical Trial.

4

Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.

Bitton RJ, Figg WD, Venzon DJ, Dalakas MC, Bowden C, Headlee D, Reed E, Myers CE, Cooper MR. Bitton RJ, et al. Among authors: headlee d. J Clin Oncol. 1995 Sep;13(9):2223-9. doi: 10.1200/JCO.1995.13.9.2223. J Clin Oncol. 1995. PMID: 7666080 Clinical Trial.

5

Hypothyroidism associated with aminoglutethimide in patients with prostate cancer.

Figg WD, Thibault A, Sartor AO, Mays D, Headlee D, Calis KA, Cooper MR. Figg WD, et al. Among authors: headlee d. Arch Intern Med. 1994 May 9;154(9):1023-5. Arch Intern Med. 1994. PMID: 8179445

6

A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.

Bowden CJ, Figg WD, Dawson NA, Sartor O, Bitton RJ, Weinberger MS, Headlee D, Reed E, Myers CE, Cooper MR. Bowden CJ, et al. Among authors: headlee d. Cancer Chemother Pharmacol. 1996;39(1-2):1-8. doi: 10.1007/s002800050531. Cancer Chemother Pharmacol. 1996. PMID: 8995493 Clinical Trial.

7

Bergan RC, Walls RG, Figg WD, Dawson NA, Headlee D, Tompkins A, Steinberg SM, Reed E. Bergan RC, et al. Among authors: headlee d. J Natl Med Assoc. 1997 Sep;89(9):622-8. J Natl Med Assoc. 1997. PMID: 9302860 Free PMC article.

8

Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.

Dawson N, Figg WD, Brawley OW, Bergan R, Cooper MR, Senderowicz A, Headlee D, Steinberg SM, Sutherland M, Patronas N, Sausville E, Linehan WM, Reed E, Sartor O. Dawson N, et al. Among authors: headlee d. Clin Cancer Res. 1998 Jan;4(1):37-44. Clin Cancer Res. 1998. PMID: 9516950 Clinical Trial.

9

A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.

Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho HK, Figg WD, Tompkins A, Linehan WM, Kohler D, Steinberg SM, Blagosklonny MV. Bergan RC, et al. Among authors: headlee d. Clin Cancer Res. 1999 Sep;5(9):2366-73. Clin Cancer Res. 1999. PMID: 10499606 Clinical Trial.

10

A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer.

Senderowicz AM, Reid R, Headlee D, Abornathy T, Horti J, Lush RM, Reed E, Figg WD, Sausville EA. Senderowicz AM, et al. Among authors: headlee d. Urol Int. 1999;63(2):120-5. doi: 10.1159/000030430. Urol Int. 1999. PMID: 10592501 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters